title: Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.
authors.forename: V
authors.initials: V
authors.lastname: Goede
authors.forename: K
authors.initials: K
authors.lastname: Fischer
authors.forename: R
authors.initials: R
authors.lastname: Busch
authors.forename: U
authors.initials: U
authors.lastname: Jaeger
authors.forename: M-S
authors.initials: MS
authors.lastname: Dilhuydy
authors.forename: N
authors.initials: N
authors.lastname: Wickham
authors.forename: S
authors.initials: S
authors.lastname: De Guibert
authors.forename: M
authors.initials: M
authors.lastname: Ritgen
authors.forename: A W
authors.initials: AW
authors.lastname: Langerak
authors.forename: G
authors.initials: G
authors.lastname: Bieska
authors.forename: A
authors.initials: A
authors.lastname: Engelke
authors.forename: K
authors.initials: K
authors.lastname: Humphrey
authors.forename: M
authors.initials: M
authors.lastname: Wenger
authors.forename: M
authors.initials: M
authors.lastname: Hallek
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D002699:Chlorambucil / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D002699:Chlorambucil; C543332:obinutuzumab